Design Therapeutics (DSGN) Return on Sales (2020)
Design Therapeutics recorded quarterly Return on Sales of 1.17% in Q4 2020, up 1.8% quarter-over-quarter from 1.19% in Q3 2020.
Design Therapeutics' Return on Sales history runs 1 years deep, the most recent figure standing at 1.17% for Q4 2020.
- In Q4 2020, Return on Sales changed N/A year-over-year to 1.17%; the TTM figure through Dec 2020 stood at 0.37% (changed N/A YoY), while the FY2020 annual figure was 0.37%, changed N/A from the prior year.
- Return on Sales came in at 1.17% for Q4 2020 at Design Therapeutics, up from 1.19% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.04% in Q1 2020 to a low of 1.19% in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.00% |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -1.17% |
| Sep 30, 2020 | -1.19% |
| Jun 30, 2020 | -0.47% |
| Mar 31, 2020 | -0.04% |